|
2024
|
Invention
|
Enantiomers of a2-73, analogues, and sigma agonist activity.
A pharmaceutical preparation compri... |
|
|
Invention
|
A2-73 crystalline polymorph compositions of matter and methods of use thereof.
The present discl... |
|
|
Invention
|
Methods of using surrogate biomarkers in sigma-1 receptor therapy. The present disclosure provide... |
|
|
Invention
|
Treatment of cardiac dysfunction.
A method for treatment of cardiac dysfunction comprising admin... |
|
|
Invention
|
Treatment and prevention of cerebral atrophy. The present disclosure provides methods and kits fo... |
|
|
Invention
|
Analgesic therapeutic and method, 1-(3-4(((1r,3s,5s)-adamantan-1-yl)(phenyl)methyl)propyl)-4-meth... |
|
2023
|
Invention
|
Neurodevelopmental disorder therapy.
This invention addresses tetrahydro-N, N-dimethyl-2,2diphen... |
|
|
Invention
|
A2-73 as a therapeutic for insomnia, anxiety and agitation. A2-73 is a useful therapeutic in the ... |
|
|
Invention
|
Therapy selection and treatment of neurodegenerative disorders. The present disclosure provides m... |
|
|
Invention
|
Compositions and methods for prevention of cognitive decline caused by degenerative diseases |
|
|
Invention
|
Compositions and methods for prevention of cognitive decline caused by degenerative diseases. The... |
|
|
Invention
|
A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure ... |
|
|
Invention
|
Crystal forms of tetrahydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine, processes of making ... |
|
2022
|
Invention
|
Therapy selection and treatment of neurodegenerative disorders.
The present disclosure provides ... |
|
|
Invention
|
Sigma-1 receptor agonist systolic blood pressure therapy. A method for lowering systolic blood pr... |
|
|
Invention
|
A2-73 crystalline polymorph compositions of matter and methods of use thereof. The present disclo... |
|
|
Invention
|
Enantiomers of a2-73, analogues, and sigma agonist activity. A2-73.
A2-73 and determining the le... |
|
|
Invention
|
Neurodevelopmental disorder therapy. This invention addresses tetrahydro-N, N-dimethyl-2,2dipheny... |
|
|
Invention
|
A2-73 as a therapeutic for insomnia, anxiety, and agitation. A2-73 is a useful therapeutic in the... |
|
|
Invention
|
Prevention and treatment of coronavirus infection. Provided herein are compositions comprising on... |
|
2021
|
Invention
|
Treatment of cardiac dysfunction. A method for treatment of cardiac dysfunction comprising admini... |
|
|
Invention
|
Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes... |
|
2020
|
Invention
|
Anavex2-73 for the treatment of genetic neurodevelopmental disorders.
The present invention prov... |
|
|
Invention
|
Anavex2-73 for the treatment of genetic neurodevelopmental disorders. The present invention provi... |
|
2019
|
Invention
|
Neurodevelopmental disorder therapy. This invention addresses tetrahydro-N,N-dimethyl-2,2-dipheny... |
|
|
Invention
|
Anavex2-73 for the treatment of alzheimer's disease. Composition and method for treatment of Alzh... |
|
|
Invention
|
Optimized sigma-1 agonist method of responder selection and treatment. The present disclosure pro... |
|
|
Invention
|
Analgesic therapeutic and method, 1-(3-4(((1 r,3s,5s)-adamantan-1-yl)(phenyl)methyl)propyl)-4-met... |
|
2017
|
Invention
|
Crystalline form of anavex2-73 for the treatment of alzheimer's disease. Composition and method f... |
|
2015
|
G/S
|
Pharmaceutical preparations for the treatment of neurological conditions including Alzheimer's di... |
|
|
G/S
|
Pharmaceutical research and development |
